Covid-19 Vaccine, Conjugate

What it is and how it works

Contains the recombinant receptor-binding domain (RBD) of the SARS-CoV-2 spike protein chemically conjugated to a carrier protein such as tetanus toxoid, usually adsorbed on aluminium hydroxide. Conjugation enhances T-cell help and the neutralising antibody response against the spike RBD.

Indications

Active immunisation to prevent COVID-19 in the age groups specified for each product.

Dosage and administration (summary)

Given by intramuscular injection according to the national immunisation protocol and the product’s schedule.

Contraindications

Severe allergic reaction to a previous dose or to any component, including the carrier protein.

Warnings and precautions

Appropriate treatment for anaphylaxis must be available and recipients observed after vaccination. Postpone vaccination in acute severe febrile illness; use with caution in thrombocytopenia or coagulation disorders. Immunosuppressed individuals may have a reduced response.

Pregnancy

Data are limited; use in pregnancy only in line with national guidance after benefit–risk assessment.

Storage and supply

Store refrigerated at 2–8 °C; do not freeze.

Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.